BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-nickens P, Nkulikiyinka R, Lewis GD, Gomberg-maitland M, O’connor CM, Stockbridge N, Califf RM, Konstam MA, Januzzi JL, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM. Heart Failure With Preserved Ejection Fraction Expert Panel Report. JACC: Heart Failure 2018;6:619-32. [DOI: 10.1016/j.jchf.2018.06.008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 14.8] [Reference Citation Analysis]
Number Citing Articles
1 Ishida A, Isotani A, Fujisawa M, Del Saz EG, Okumiya K, Kimura Y, Manuaba IIB, Rantetampang AL, Ohya Y, Matsubayashi K. Effects of a Low-Salt and High-Potassium Diet on Arterial Stiffness and Left Ventricular Function in Indigenous Papuans. J Am Heart Assoc 2021;10:e021789. [PMID: 34873920 DOI: 10.1161/JAHA.121.021789] [Reference Citation Analysis]
2 Parajuli DR, Kourbelis C, Franzon J, Newman P, Mckinnon RA, Shakib S, Whitehead D, Clark RA. Effectiveness of the Pharmacist-Involved Multidisciplinary Management of Heart Failure to Improve Hospitalizations and Mortality Rates in 4630 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure 2019;25:744-56. [DOI: 10.1016/j.cardfail.2019.07.455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
3 Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019;124:1598-1617. [PMID: 31120821 DOI: 10.1161/circresaha.119.313572] [Cited by in Crossref: 165] [Cited by in F6Publishing: 74] [Article Influence: 82.5] [Reference Citation Analysis]
4 Guan Z, Liu S, Wang Y, Meng P, Zheng X, Jia D, Yang J, Ma C. Left ventricular systolic dysfunction potentially contributes to the symptoms in heart failure with preserved ejection fraction. Echocardiography 2019;36:1825-33. [PMID: 31573711 DOI: 10.1111/echo.14496] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
5 Holmes JB, Doh CY, Mamidi R, Li J, Stelzer JE. Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery. Expert Opin Drug Discov 2020;15:457-69. [PMID: 32067508 DOI: 10.1080/17460441.2020.1722637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kessler EL, Oerlemans MIFJ, van den Hoogen P, Yap C, Sluijter JPG, de Jager SCA. Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. J Cardiovasc Transl Res 2021;14:63-74. [PMID: 32444946 DOI: 10.1007/s12265-020-10026-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Nanayakkara S, Kaye DM, Marwick TH. Resting and Exercise Doppler Hemodynamics: How and Why? Heart Fail Clin 2019;15:229-39. [PMID: 30832814 DOI: 10.1016/j.hfc.2018.12.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Yoo JH, Park SW, Jun JE, Jin SM, Hur KY, Lee MK, Kang M, Kim G, Kim JH. Relationship between low skeletal muscle mass, sarcopenic obesity and left ventricular diastolic dysfunction in Korean adults. Diabetes Metab Res Rev 2021;37:e3363. [PMID: 32521113 DOI: 10.1002/dmrr.3363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens M, Heymans S, Beussink-Nelson L, Shah SJ, van Empel VPM. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:413-21. [PMID: 31472035 DOI: 10.1002/ejhf.1614] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
10 Lakhani I, Leung KSK, Tse G, Lee APW. Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. Front Physiol 2019;10:874. [PMID: 31333505 DOI: 10.3389/fphys.2019.00874] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
11 Chen J, Li M, Hao B, Cai Y, Li H, Zhou W, Song Y, Wang S, Liu H. Waist to height ratio is associated with an increased risk of mortality in Chinese patients with heart failure with preserved ejection fraction. BMC Cardiovasc Disord 2021;21:263. [PMID: 34049494 DOI: 10.1186/s12872-021-02080-9] [Reference Citation Analysis]
12 Nanayakkara S, Byrne M, Mak V, Carter K, Dean E, Kaye DM. Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2020;9:e015026. [PMID: 32552264 DOI: 10.1161/JAHA.119.015026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
13 Agrawal V, D'Alto M, Naeije R, Romeo E, Xu M, Assad TR, Robbins IM, Newman JH, Pugh ME, Hemnes AR, Brittain EL. Echocardiographic Detection of Occult Diastolic Dysfunction in Pulmonary Hypertension After Fluid Challenge. J Am Heart Assoc 2019;8:e012504. [PMID: 31475602 DOI: 10.1161/JAHA.119.012504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Roh J, Hill JA, Singh A, Valero-Muñoz M, Sam F. Heart Failure With Preserved Ejection Fraction: Heterogeneous Syndrome, Diverse Preclinical Models. Circ Res 2022;130:1906-25. [PMID: 35679364 DOI: 10.1161/CIRCRESAHA.122.320257] [Reference Citation Analysis]
15 Beaubien-souligny W, Brand FZA, Lenoir M, Amsallem M, Haddad F, Denault AY. Assessment of Left Ventricular Diastolic Function by Transesophageal Echocardiography Before Cardiopulmonary Bypass: Clinical Implications of a Restrictive Profile. Journal of Cardiothoracic and Vascular Anesthesia 2019;33:2394-401. [DOI: 10.1053/j.jvca.2019.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Metkus TS, Stephens RS, Schulman S, Hsu S, Morrow DA, Eid SM. Respiratory support in acute heart failure with preserved vs reduced ejection fraction. Clin Cardiol 2020;43:320-8. [PMID: 31825125 DOI: 10.1002/clc.23317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Segar MW, Singh S, Goyal P, Hummel SL, Maurer MS, Forman DE, Butler J, Pandey A. Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. J Am Geriatr Soc 2021. [PMID: 34050919 DOI: 10.1111/jgs.17218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL Jr, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, O'Connor CM. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. Eur J Heart Fail 2020;22:2175-86. [PMID: 33017862 DOI: 10.1002/ejhf.2018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Qiu B, Zhao P, Shen L, Qiao S, Li G, Deng B, Zhou D, Wei Y. Improvement of Shen'ge formula on heart function in diastolic heart failure: A protocol for randomized, double-blind, placebo-controlled clinical study. Medicine (Baltimore) 2021;100:e25383. [PMID: 33787645 DOI: 10.1097/MD.0000000000025383] [Reference Citation Analysis]
20 Santas E, De la Espriella R, Chorro FJ, Palau P, Miñana G, Heredia R, Amiguet M, Merenciano H, Sanchis J, Lupón J, Bayés-Genís A, Núñez J. Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure With Preserved Ejection Fraction. J Clin Med 2020;9:E831. [PMID: 32197527 DOI: 10.3390/jcm9030831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Sabbah MS, Fayyaz AU, de Denus S, Felker GM, Borlaug BA, Dasari S, Carter RE, Redfield MM. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2020;13:e006414. [PMID: 32809874 DOI: 10.1161/CIRCHEARTFAILURE.119.006414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Sahlin D, Rezanezad B, Edvinsson ML, Bachus E, Melander O, Gerward S. Self-care Management Intervention in Heart Failure (SMART-HF): A Multicenter Randomized Controlled Trial. J Card Fail 2021:S1071-9164(21)00245-1. [PMID: 34161807 DOI: 10.1016/j.cardfail.2021.06.009] [Reference Citation Analysis]
23 Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V, Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C Jr, Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail 2020;8:712-24. [PMID: 32653448 DOI: 10.1016/j.jchf.2020.04.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
24 Clark KAA, Velazquez EJ. Heart Failure With Preserved Ejection Fraction: Time for a Reset. JAMA 2020;324:1506-8. [PMID: 33079136 DOI: 10.1001/jama.2020.15566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Patel RB, Vaduganathan M, Felker GM, Butler J, Redfield MM, Shah SJ. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). Am J Cardiol 2019;123:1660-6. [PMID: 30876658 DOI: 10.1016/j.amjcard.2019.02.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Agrawal V, Hemnes AR. Authors' reply: role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. Pulm Circ 2020;10:2045894020910979. [PMID: 32206307 DOI: 10.1177/2045894020910979] [Reference Citation Analysis]
27 Redfield MM, Borlaug BA. Quality of Life and Exercise Ability in Heart Failure With Preserved Ejection Fraction: No Time for Therapeutic Complacency. JAMA 2021;326:1913-5. [PMID: 34783856 DOI: 10.1001/jama.2021.15874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gentile F, Ghionzoli N, Borrelli C, Vergaro G, Pastore MC, Cameli M, Emdin M, Passino C, Giannoni A. Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. Eur J Prev Cardiol 2021:zwab077. [PMID: 33963839 DOI: 10.1093/eurjpc/zwab077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Agrawal V, Fortune N, Yu S, Fuentes J, Shi F, Nichols D, Gleaves L, Poovey E, Wang TJ, Brittain EL, Collins S, West JD, Hemnes AR. Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. Pulm Circ 2019;9:2045894019878599. [PMID: 31903184 DOI: 10.1177/2045894019895452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
30 Weerts J, Mourmans SGJ, Barandiarán Aizpurua A, Schroen BLM, Knackstedt C, Eringa E, Houben AJHM, van Empel VPM. The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction. Biomolecules 2022;12:278. [DOI: 10.3390/biom12020278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Volpe M, Gallo G. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. Cardiovasc Res 2021;117:1992-4. [PMID: 33231613 DOI: 10.1093/cvr/cvaa334] [Reference Citation Analysis]
32 Jaconiano E, Moreira-Gonçalves D. Unveiling the role of exercise training in targeting the inflammatory paradigm of heart failure with preserved ejection fraction: a narrative review. Heart Fail Rev 2021. [PMID: 34244870 DOI: 10.1007/s10741-021-10138-1] [Reference Citation Analysis]
33 Pagel PS, Tawil JN, Boettcher BT, Izquierdo DA, Lazicki TJ, Crystal GJ, Freed JK. Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. J Cardiothorac Vasc Anesth 2021;35:1839-59. [PMID: 32747202 DOI: 10.1053/j.jvca.2020.07.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Hungerford SL, Kearney K, Bart NK. Editorial for "Non-Contrast Cardiac MRI Predictors of Heart Failure Hospitalization in Heart Failure With Preserved Ejection Fraction". J Magn Reson Imaging 2021. [PMID: 34551180 DOI: 10.1002/jmri.27933] [Reference Citation Analysis]
35 Zhou Y, Fu L, Sun J, Zhu Z, Xing Z, Zhou S, Tai S, Wang Y. Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF. Front Cardiovasc Med 2021;8:698117. [PMID: 34595217 DOI: 10.3389/fcvm.2021.698117] [Reference Citation Analysis]
36 Jin G, Wang L, Ma J. Inhibiting STAT5 significantly attenuated Ang II-induced cardiac dysfunction and inflammation. Eur J Pharmacol 2022;915:174689. [PMID: 34919891 DOI: 10.1016/j.ejphar.2021.174689] [Reference Citation Analysis]
37 Wu H, Yang H, Rhee JW, Zhang JZ, Lam CK, Sallam K, Chang ACY, Ma N, Lee J, Zhang H, Blau HM, Bers DM, Wu JC. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. Eur Heart J. 2019;40:3685-3695. [PMID: 31219556 DOI: 10.1093/eurheartj/ehz326] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
38 Palazzuoli A, Caravita S, Paolillo S, Ghio S, Tocchetti CG, Ruocco G, Correale M, Ambrosio G, Perrone Filardi P, Senni M; Italian Society of Cardiology Heart Failure Study Group. Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. Prog Cardiovasc Dis 2021;67:89-97. [PMID: 33839166 DOI: 10.1016/j.pcad.2021.03.007] [Reference Citation Analysis]
39 Roh JD, Houstis N, Yu A, Chang B, Yeri A, Li H, Hobson R, Lerchenmüller C, Vujic A, Chaudhari V, Damilano F, Platt C, Zlotoff D, Lee RT, Shah R, Jerosch-Herold M, Rosenzweig A. Exercise training reverses cardiac aging phenotypes associated with heart failure with preserved ejection fraction in male mice. Aging Cell 2020;19:e13159. [PMID: 32441410 DOI: 10.1111/acel.13159] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
40 Besler C, Rommel KP, Kresoja KP, Mörbitz J, Kirsten H, Scholz M, Klingel K, Thiery J, Burkhardt R, Büttner P, Adams V, Thiele H, Lurz P. Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction. ESC Heart Fail 2021;8:1861-72. [PMID: 33787083 DOI: 10.1002/ehf2.13327] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Scheffer M, Driessen-Waaijer A, Hamdani N, Landzaat JWD, Jonkman NH, Paulus WJ, van Heerebeek L. Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial. ESC Heart Fail 2020. [PMID: 33073523 DOI: 10.1002/ehf2.13055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
42 Yamanaka S, Sakata Y, Nochioka K, Miura M, Kasahara S, Sato M, Aoyanagi H, Fujihashi T, Hayashi H, Shiroto T, Sugimura K, Takahashi J, Miyata S, Shimokawa H; CHART-2 Investigators. Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction. Eur J Heart Fail 2020;22:2258-68. [PMID: 32592517 DOI: 10.1002/ejhf.1945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Abramov D, Parwani P. Diving Into the Diagnostic Score Algorithms of Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2021;8:665424. [PMID: 34179132 DOI: 10.3389/fcvm.2021.665424] [Reference Citation Analysis]
44 Teramoto K, Sengelov M, West E, Santos M, Nadruz W, Skali H, Shah AM. Association of pulmonary hypertension and right ventricular function with exercise capacity in heart failure. ESC Heart Fail 2020;7:1635-44. [PMID: 32385945 DOI: 10.1002/ehf2.12717] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Cosiano MF, Tobin R, Mentz RJ, Greene SJ. Physical Functioning in Heart Failure With Preserved Ejection Fraction. J Card Fail 2021:S1071-9164(21)00156-1. [PMID: 33991684 DOI: 10.1016/j.cardfail.2021.04.013] [Reference Citation Analysis]
46 Howden EJ, Ruiz-Carmona S, Claeys M, De Bosscher R, Willems R, Meyns B, Verbelen T, Maleux G, Godinas L, Belge C, Bogaert J, Claus P, La Gerche A, Delcroix M, Claessen G. Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation 2021;143:2061-73. [PMID: 33853383 DOI: 10.1161/CIRCULATIONAHA.120.052899] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Abboud A, Nguonly A, Bean A, Brown KJ, Chen RF, Dudzinski D, Fiseha N, Joice M, Kimaiyo D, Martin M, Taylor C, Wei K, Welch M, Zlotoff DA, Januzzi JL, Gaggin HK. Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart 2021;8:e001704. [PMID: 34663746 DOI: 10.1136/openhrt-2021-001704] [Reference Citation Analysis]
48 Teramoto K, Santos M, Claggett B, John JE, Solomon SD, Kitzman D, Folsom AR, Cushman M, Matsushita K, Skali H, Shah AM. Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. PLoS Med 2020;17:e1003361. [PMID: 33057391 DOI: 10.1371/journal.pmed.1003361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Laforgia P, Bandera F, Alfonzetti E, Guazzi M. Exercise chronotropic incompetence phenotypes the level of cardiovascular risk and exercise gas exchange impairment in the general population. An analysis of the Euro-EX prevention trial. Eur J Prev Cardiol 2020;27:526-35. [PMID: 31345056 DOI: 10.1177/2047487319863506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
50 Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res 2021;128:1421-34. [PMID: 33983838 DOI: 10.1161/CIRCRESAHA.121.318172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 D'Amario D, Borovac JA, Crea F. Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning. Eur J Heart Fail 2021;23:773-5. [PMID: 33247863 DOI: 10.1002/ejhf.2069] [Reference Citation Analysis]
52 Wang J, Lu Y, Min X, Yuan T, Wei J, Cai Z. The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study. Front Cardiovasc Med 2021;8:648212. [PMID: 33778026 DOI: 10.3389/fcvm.2021.648212] [Reference Citation Analysis]
53 Kurose H. Cardiac Fibrosis and Fibroblasts. Cells 2021;10:1716. [PMID: 34359886 DOI: 10.3390/cells10071716] [Reference Citation Analysis]
54 Mizuno A, Miyashita M, Kohno T, Tokuda Y, Fujimoto S, Nakamura M, Takayama M, Niwa K, Fukuda T, Ishimatsu S, Kinoshita S, Oishi S, Mochizuki H, Utsunomiya A, Takada Y, Ochiai R, Mochizuki T, Nagao K, Yoshida S, Hayashi A, Sekine R, Anzai T. Quality indicators of palliative care for acute cardiovascular diseases. J Cardiol 2020;76:177-83. [PMID: 32199753 DOI: 10.1016/j.jjcc.2020.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sugimoto T. Acute Decompensated Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction. Heart Fail Clin 2020;16:201-9. [PMID: 32143764 DOI: 10.1016/j.hfc.2019.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Spitaleri G, Lupón J, Domingo M, Santiago-Vacas E, Codina P, Zamora E, Cediel G, Santesmases J, Diez-Quevedo C, Troya MI, Boldo M, Altmir S, Alonso N, González B, Núñez J, Bayes-Genis A. Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. Sci Rep 2021;11:732. [PMID: 33436787 DOI: 10.1038/s41598-020-79926-3] [Reference Citation Analysis]
57 Abboud A, Januzzi JL. Reverse Cardiac Remodeling and ARNI Therapy. Curr Heart Fail Rep 2021;18:71-83. [DOI: 10.1007/s11897-021-00501-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Shi K, Yang MX, Huang S, Yan WF, Qian WL, Li Y, Guo YK, Yang ZG. Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction. Cardiovasc Diabetol 2021;20:185. [PMID: 34521391 DOI: 10.1186/s12933-021-01379-3] [Reference Citation Analysis]
59 Brubaker PH, Avis T, Rejeski WJ, Mihalko SE, Tucker WJ, Kitzman DW. Exercise Training Effects on the Relationship of Physical Function and Health-Related Quality of Life Among Older Heart Failure Patients With Preserved Ejection Fraction. J Cardiopulm Rehabil Prev 2020;40:427-33. [PMID: 32604218 DOI: 10.1097/HCR.0000000000000507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
60 Silverman DN, Plante TB, Infeld M, Callas PW, Juraschek SP, Dougherty GB, Meyer M. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open 2019;2:e1916598. [PMID: 31800067 DOI: 10.1001/jamanetworkopen.2019.16598] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
61 Parcha V, Malla G, Kalra R, Patel N, Sanders-van Wijk S, Pandey A, Shah SJ, Arora G, Arora P. Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems. ESC Heart Fail 2021;8:2089-102. [PMID: 33709628 DOI: 10.1002/ehf2.13288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Rosalia L, Ozturk C, Shoar S, Fan Y, Malone G, Cheema FH, Conway C, Byrne RA, Duffy GP, Malone A, Roche ET, Hameed A. Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci 2021;6:772-95. [PMID: 34754993 DOI: 10.1016/j.jacbts.2021.06.002] [Reference Citation Analysis]
63 Badrov MB, Mak S, Floras JS. Cardiovascular Autonomic Disturbances in Heart Failure With Preserved Ejection Fraction. Can J Cardiol 2021;37:609-20. [PMID: 33310140 DOI: 10.1016/j.cjca.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
64 Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-56. [PMID: 32483830 DOI: 10.1002/ejhf.1858] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 37.0] [Reference Citation Analysis]
65 Baker C, Perkins SL, Schoenborn E, Biondi NL, Bowers RD. Pharmacotherapy Considerations in Heart Failure with Mildly-Reduced Ejection Fraction. J Pharm Pract 2021;:8971900211027315. [PMID: 34166127 DOI: 10.1177/08971900211027315] [Reference Citation Analysis]